Over the last 3 years a new device for non-invasive body contouring has been extensively tested under approved clinical protocols. After demonstrating the clinical safety in the treatment of over 60 patients in Israel, a multi center trial was initiated. Since August 2004, three sites have been set up in London, UK, Dallas, Texas, and Santa Monica, California. According to the protocol, 33 patients were enrolled in each site, 27 serving as the treatment group and 6 serving as controls. Healthy volunteers, age ranging between 18-65 years, subcutaneous fat > 1.5cm, were enrolled. The volunteers were treated once over a single anatomical site, i.e. abdomen, flanks or external thighs. Follow up post treatment included visits on days 1, 3, 7, 14, 21, 28, 56, and 84. Visits included blood work up, physical examination, photography, weight and circumference measurements of the treated areas as well as control areas, liver ultrasonography and two point discrimination test of the skin overlying the treated area before and one month after the treatment. Results: statistically significant results were recorded in circumference reduction in all areas. Changes in circumference ranged among 1-2.5 cm (0.4-1 inch) after a single treatment. The results were long lasting, as demonstrated over 84 days follow up. No adverse effects were noted with the exception of one patient who did not have sufficient subcutaneous fat and suffered from skin burn that healed spontaneously. All blood exams returned within normal ranges post treatment. Two point discrimination tests did not document any changes in skin sensation. Liver ultrasonography did not reveal any fatty liver changes in one month follow up. During the treatment and 2 weeks after there was no change in blood oxygenation levels as documented by pulse oximetry. Patients' and physicians' satisfaction was recorded on a satisfaction questionnaire. The results of the study demonstrated the safety and the efficacy of the new “walk-in walk-out” type of non invasive procedure for body contouring in both genders (1/3 male patients), all races and over different anatomical sites.